STAT Summit 2020

Nov 16-19Online#statsummit

About

The 2020 STAT Summit: What’s next?

The coronavirus pandemic has reset our expectations of what is possible. New medicines and vaccines are being developed at a previously unimaginable pace. Telemedicine has replaced the doctor’s office. Now, we’re starting to figure out how the world has been reshaped in the wake of Covid-19, pushing us to reexamine long-standing inequities in health care and make new discoveries at top speed.

As we work to navigate this new order, we invite you to join us — and some of the greatest minds in science and medicine — for our virtual 2020 STAT Summit, where we’ll answer the big question on everyone’s mind: What’s next?

The 2020 STAT Summit is complete

Thank you to the speakers and all who tuned into our second-annual STAT Summit. Catch up with coverage from the event and sign up for announcements about future summits.

Speakers

Hear from these industry-shaping speakers

Apply today to be considered for speaking opportunities for future events.

Please note that all speakers are subject to change.

Behzad Aghazadeh, Ph.D.

Managing Partner & Portfolio Manager, Avoro Capital Advisors

Peter Bach M.D., MAPP

Director, Center for Health Policy and Outcomes

Sponsor Speaker

Liz Barrett

President and Chief Executive Officer, UroGen Pharma

Regina Barzilay, Ph.D.

Delta Electronics Professor, Department of Electrical Engineering and Computer Science; Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology

Angela M. Belcher, Ph.D.

James Mason Crafts Professor of Biological Engineering and Materials Science, Massachusetts Institute of Technology

Sponsor Speaker

Arie Belldegrun, M.D., F.A.C.S.

Executive Chairman and Co-founder, Allogene Therapeutics

STAT Moderator

Rick Berke

Co-founder & Executive Editor, STAT

STAT Moderator

Eric Boodman

General Assignment Reporter, STAT

Albert Bourla, DVM, Ph.D.

Chairman and Chief Executive Officer, Pfizer

Robert A. Bradway

Chairman and CEO, Amgen

STAT Moderator

Helen Branswell

Senior Writer, Infectious Disease, STAT

STAT Moderator

Erin Brodwin

Health Tech Correspondent, STAT

STAT Moderator

Shraddha Chakradhar

Reporter, Morning Rounds Writer, STAT

Sponsor Speaker

David Chang, M.D., Ph.D.

President, Chief Executive Officer and Co-founder, Allogene Therapeutics

Janice Chen, Ph.D.

Co-founder and CTO, Mammoth Biosciences

Chelsea Clinton

Vice Chair, Clinton Foundation

Tony Coles, M.D.

Executive Chairman & CEO, Cerevel Therapeutics

David Cordani

President and CEO, Cigna Corporation

Tshaka Cunningham, Ph.D.

Co-Founder and Chief Scientific Officer, TruGenomix Inc.

Jennifer A. Doudna, Ph.D.

Biochemist and Co-inventor of CRISPR Technology

Sponsor Speaker

Giulio F. Draetta, M.D., Ph.D.,

Chief Scientific Officer, The University of Texas MD Anderson Cancer Center

Congresswoman Anna G. Eshoo

California’s 18th District

Anthony S. Fauci, M.D.

Director of the National Institute of Allergy and Infectious Diseases (NIAID)

David Feinberg, M.D.

Head of Google Health

STAT Moderator

Adam Feuerstein

Senior Writer, Biotech, STAT

STAT Moderator

Nicholas Florko

Washington correspondent, STAT

STAT Moderator

Damian Garde

National Biotech Reporter, STAT

Bill Gates

Co-chair, Bill & Melinda Gates Foundation

Walid Gellad, M.D., MPH

Director, Center for Pharmaceutical Policy and Prescribing, University of Pittsburgh School of Medicine

STAT Moderator

Gideon Gil

Managing Editor, STAT

Sponsor Speaker

Stephen Gruber, M.D., M.P.H., Ph.D.

Director of the Center for Precision Medicine; Medical Oncologist, City of Hope

Priti Hegde, Ph.D.

Chief Scientific Officer, Foundation Medicine

Sponsor Speaker

Scott M. Heimlich, Ed.D.

Vice President, Amgen Foundation; Director of Philanthropy, Amgen

STAT Moderator

Linda Henry

CEO, Boston Globe Media Partners

STAT Moderator

Matthew Herper

Senior Writer, Medicine; Editorial Director of Events, STAT

Samit Hirawat, M.D.

Executive Vice President, Chief Medical Officer, Global Drug Development, Bristol Myers Squibb

Pearl Huang, Ph.D.

President & CEO, Cygnal Therapeutics

Akiko Iwasaki, Ph.D.

Waldemar Von Zedtwitz Professor of Immunobiology and Molecular, Cellular and Developmental Biology, Yale University; Investigator, Howard Hughes Medical Institute

STAT Moderator

Andrew Joseph

General Assignment Reporter, STAT

Dara Kass, M.D., FACEP

Emergency Medicine Physician, Founder of FemInEM

Sekar Kathiresan, M.D.

Co-Founder and Chief Executive Officer, Verve Therapeutics

Reshma Kewalramani, M.D.

CEO and President, Vertex Pharmaceuticals

Dean Li, M.D. Ph.D.

Senior Vice President, Discovery Sciences and Translational Medicine, Merck Research Laboratories

Ted W. Love, M.D.

President and Chief Executive Officer, Global Blood Therapeutics

Michelle McMurry-Heath, M.D., Ph.D.

President & CEO, Biotechnology Innovation Organization (BIO)

Sponsor Speaker

Kabir Nath

President and CEO, Otsuka North America Pharmaceutical Business

Benjamin L. Oakes, Ph.D.

Co-founder, President, and CEO, Scribe Therapeutics

Deval L. Patrick

Former Governor of Massachusetts; Founder & Chairman, TogetherFUND PAC

Sponsor Speaker

Peter WT Pisters, M.D., M.H.C.M.

President, The University of Texas MD Anderson Cancer Center

Sponsor Speaker

Andrew Plump, M.D., Ph.D.

President, Research & Development, Takeda Pharmaceutical Company

Sponsor Speaker

John Reed, M.D. Ph.D.

Executive Vice President, Global Head of Research & Development, Sanofi

Aviv Regev, Ph.D.

Executive Vice President, Genentech Research and Early Development

Sponsor Speaker

David A. Ricks

Chairman and Chief Executive Officer, Eli Lilly and Company; Incoming Chairman of the Board, PhRMA

Caitlin M. Rivers, Ph.D.

Assistant Professor, Johns Hopkins Bloomberg School of Public Health

STAT Moderator

Casey Ross

National Technology Correspondent, STAT

Jonathan Rothberg, Ph.D.

Chairman of 4Catalyzer (Butterfly Network, Quantum-Si, AI Therapeutics, Hyperfine, Tesseract Health, EpilepsyCo, Homodeus)

Sponsor Speaker

Mace L. Rothenberg, M.D.

Chief Medical Officer, Pfizer Inc.

George Scangos, Ph.D.

Chief Executive Officer and Director, Vir Biotechnology

Leonard S. Schleifer, M.D., Ph.D.

Co-Founder, President, and Chief Executive Officer, Regeneron

Sponsor Speaker

Lynn Seely, M.D.

Chief Executive Officer, Myovant Sciences

Kaylene Sheran

Student, Lasell University

STAT Moderator

Ed Silverman

Pharmalot Columnist, Senior Writer, STAT

Sponsor Speaker

Melissa Starovasnik, Ph.D.

Senior Scientific Advisor, Research, Genentech

STAT Moderator

Megan Thielking

News Editor, STAT

Sponsor Speaker

Stephen J. Ubl

President and Chief Executive Officer, PhRMA

STAT Moderator

Bina Venkataraman

editorial page editor, The Boston Globe

Bert Vogelstein, M.D.

Co-director of the Ludwig Center, John Hopkins Kimmel Cancer Center; Investigator, Howard Hughes Medical Institute

Dame Emma Walmsley

Chief Executive Officer, GlaxoSmithKline

Anne Wojcicki

CEO and Co-Founder, 23andMe

George D. Yancopoulos, M.D., Ph.D.

Co-Founder, President, and Chief Scientific Officer, Regeneron

Agenda

What’s next?

It’s the question on everyone’s mind as we navigate the new post-Covid order, and one that we sought to answer at our November STAT Summit. This virtual event was hosted online from Nov. 16-19, 2020. Each day started at 1 p.m. ET, and programming explored the development of new medicines and treatments, telemedicine, and the future of treatment.

Check out the highlights from past year’s Summit on our archive page.

November 16

1 p.m. ET

Welcome from STAT

5 minutes

Rick Berke, co-founder & executive editor, STAT

1:05 p.m. ET

Sponsor Speaker

Welcome Remarks

5 minutes

David A. Ricks, chairman and chief executive officer, Eli Lilly; incoming chairman of the board, PhRMA

1:10 p.m. ET

What’s next for GlaxoSmithKline?

20 minutes

Dame Emma Walmsley, chief executive officer, GlaxoSmithKline Matthew Herper, senior writer, medicine, editorial director of events, STAT (moderator)

Two years in — and showing resilience during a pandemic — CEO Emma Walmsley charts GSK’s course.

1:30 p.m. ET

2020 STAT Biomedical Innovation Award

15 minutes

To be announced

Sponsor Introduction

Mace L. Rothenberg, M.D., chief medical officer, Pfizer

1:45 p.m. ET

From academia to industry

35 minutes

Sekar Kathiresan, M.D., co-founder and chief executive officer, Verve Therapeutics Dean Li, M.D., Ph.D., senior vice president Discovery Sciences and Translational Medicine, Merck Research Laboratories Aviv Regev, Ph.D., executive vice president, Genentech Research and Early Development Damian Garde, national biotech reporter, STAT (moderator)

These executives have moved from the ivory tower to the corporate frontlines. What have they learned from the experience?

2:20 p.m. ET

A patient’s quandary

15 minutes

Kaylene Sheran, student, Lasell University Eric Boodman, general assignment reporter, STAT (moderator)

The subject of Boodman’s award-winning story “The Medicine Hunters,” Sheran refused to enter a clinical trial unless the drugmaker made its medicine affordable to volunteers for life. She tells her story.

2:35 p.m. ET

Sponsor Session

Innovating against cancer

15 minutes

David Chang, M.D., Ph.D., president, chief executive officer, and co-founder, Allogene Therapeutics Arie Belldegrun, M.D., F.A.C.S., executive chairman and co-founder, Allogene Therapeutics Megan Thielking, news editor, STAT (moderator)

2:50 p.m. ET

Coffee Break

10 minutes

Sponsored by the National Pharmaceutical Council

3 p.m. ET

Welcome back from STAT

5 minutes

3:05 p.m. ET

Innovator’s dilemma

30 minutes

Jonathan Rothberg, Ph.D., chairman, 4Catalyzer (Butterfly Network, Quantum-Si, AI Therapeutics, Hyperfine, Tesseract Health, Liminal Sciences, Homodeus) Matthew Herper, senior writer, medicine; editorial director of events, STAT (moderator)

Handheld ultrasound. Portable MRI. Now, a Covid-19 test. The entrepreneur who helped put next-gen DNA sequencing on the map talks about his process, his new prospects, and the role of a serial entrepreneur in a pandemic.

3:35 p.m. ET

Covid-19: Facing winter

35 minutes

Akiko Iwasaki, Ph.D., Waldemar Von Zedtwitz Professor of Immunobiology and Molecular, Cellular and Developmental Biology; professor of molecular cellular and developmental biology; investigator, Howard Hughes Medical Institute Dara Kass, M.D., FACEP, emergency medicine physician, Founder of FemInEM Caitlin M. Rivers, Ph.D., assistant professor, Johns Hopkins Bloomberg School of Public Health Andrew Joseph, general assignment reporter, STAT (moderator)

Cases are surging across the U.S. and across Europe. What can we expect from the winter? What steps can be taken to slow the surge?

4:10 p.m. ET

Sponsor Speaker

Closing Remarks

5 minutes

Peter WT Pisters, M.D., M.H.C.M., president, The University of Texas MD Anderson Cancer Center

4:15 p.m. ET

Event close and transition to breakout sessions

4:30 p.m. ET

Breakout Sessions

45 minutes

Merck’s new research — Dean Li, M.D., Ph.D., senior vice president, Discovery Sciences and Translational Medicine, Merck Research Laboratories Hitting heart attacks, genetically — Sekar Kathiresan, M.D., co-founder and chief executive officer, Verve Therapeutics Covid-19: what’s ahead — Caitlin M. Rivers, Ph.D., assistant professor, Johns Hopkins Bloomberg School of Public Health, Dara Kass, M.D., FACEP, emergency medicine physician, Founder of FemInEM Tracking cancer with a blood test — Priti Hegde, Ph.D., chief scientific officer, Foundation Medicine Thinking like a top investor — Behzad Aghazadeh, Ph.D, managing partner & portfolio manager, Avoro Capital Advisors

Limited to participants with an Attendee Pass

November 17

1 p.m. ET

Welcome from STAT

5 minutes

1:05 p.m. ET

America’s virologist

40 minutes

Anthony S. Fauci, M.D., director, National Institute of Allergy and Infectious Diseases (NIAID); chief, NIAID Laboratory of Immunoregulation, National Institutes of Health Helen Branswell, senior writer, infectious disease, STAT (moderator)

Throughout the pandemic, Anthony Fauci’s voice has been among the most sobering and the most trusted. He joins STAT’s Helen Branswell to discuss where we are now.

1:45 p.m. ET

Sponsor Session

An industry looks ahead

10 minutes

Stephen J. Ubl, president and chief executive officer, PhRMA Matthew Herper, senior writer, medicine; editorial director of events, STAT (moderator)

1:55 p.m. ET

Interstitial

10 minutes

Gideon Gil, managing editor, STAT

To be announced

2:05 p.m. ET

Pfizer led the vaccine race. What’s next?

30 minutes

Albert Bourla, DVM, Ph.D., chairman and chief executive officer, Pfizer Matthew Herper, senior writer, medicine; editorial director of events, STAT (moderator)

Who would have expected that Pfizer would be among the first to test a Covid-19 vaccine? CEO Albert Bourla is planning to bet on the company’s labs.

2:35 p.m. ET

Introducing the 2020 STAT Wunderkinds

35 minutes

To be announced

Sponsor Introduction

Giulio F. Draetta, M.D., Ph.D., chief scientific officer, University of Texas MD Anderson Cancer Center

3:10 p.m. ET

Coffee Break

10 minutes

Sponsored by the National Pharmaceutical Council

3:20 p.m. ET

Welcome back from STAT

5 minutes

3:25 p.m. ET

Sponsor Speaker

Lessons learned collaborating to fight the pandemic

5 minutes

Andrew Plump, M.D., Ph.D., president, research & development, Takeda Pharmaceutical Company

3:30 p.m. ET

Editing science’s DNA

30 minutes

Janice Chen, Ph.D., co-founder & CTO, Mammoth Biosciences Jennifer A. Doudna, Ph.D., biochemist and co-inventor of CRISPR technology Benjamin L. Oakes, Ph.D., co-founder, president and CEO, Scribe Therapeutics Damian Garde, national biotech reporter, STAT (moderator)

Jennifer Doudna shared the chemistry Nobel Prize this year for her groundbreaking work on gene editing. But she’s been doing another kind of revision: training researchers who took leadership roles at the companies she founded. Here, she joins her proteges for a discussion of everything from Covid-19 testing to using CRISPR to create new therapies.

4:00 p.m. ET

How Cigna is changing health care

20 minutes

David Cordani, president and CEO, Cigna Corporation Casey Ross, national technology correspondent, STAT (moderator)

You know Cigna best as a health insurance company — but it’s also been making big moves in health tech, equity, and breaking down silos in the health space. CEO David Cordani talks about what’s next.

4:20 p.m. ET

Event close and transition to breakout sessions

4:30 p.m. ET

Breakout Sessions

45 minutes

Navigating rapid innovation in health care — David Cordani, president and CEO, Cigna Corporation Genetics and the brain — Tshaka Cunningham, Ph.D., co-founder and chief scientific officer, TruGenomix Inc. CRISPR diagnostics — Janice Chen, Ph.D., co-founder & CTO, Mammoth Biosciences Using CRISPR in therapeutics — Benjamin L. Oakes, Ph.D., co-founder, president and CEO, Scribe Therapeutics Inside Bristol’s pipeline — Samit Hirawat, M.D., executive vice president, chief medical officer, global drug development, Bristol Myers Squibb

Limited to participants with an Attendee Pass

5:15 p.m. ET

Special session: Bill Gates looks ahead

30 minutes

Bill Gates, co-chair, Bill & Melinda Gates Foundation Rick Berke, co-founder and executive editor, STAT (moderator)

The philanthropist warned about the threat of a pandemic again and again — including in an interview with STAT two years ago. Now he joins us with his advice on where society should invest to get out of this mess and prevent this from happening again.

November 18

1 p.m. ET

Welcome from STAT

5 minutes

1:05 p.m. ET

Biotech 2021

35 minutes

Robert A. Bradway, chairman and CEO, Amgen Ted W. Love, M.D., president and chief executive officer, Global Blood Therapeutics Reshma Kewalramani, M.D., CEO and president, Vertex Pharmaceuticals Adam Feuerstein, senior writer, biotech, STAT (moderator)

Everyone’s life was put on hold because of the pandemic. But people still need medicine even if all your meetings are on Zoom. How they coped.

1:40 p.m. ET

Google’s plan for health care

25 minutes

David Feinberg. M.D., head of Google Health Erin Brodwin, health tech correspondent, STAT (moderator)

A longtime hospital administrator, David Feinberg has said he joined Google Health in order to help billions of people. He joins STAT to explain what that means.

2:05 p.m. ET

Regeneron takes on Covid-19

25 minutes

Leonard S. Schleifer, M.D., Ph.D., co-founder, president, and chief executive officer, Regeneron George D. Yancopoulos, M.D., Ph.D., co-founder, president, and chief scientific officer, Regeneron Matthew Herper, senior writer, medicine; editorial director of events, STAT (moderator)

Regeneron made headlines when President Trump used its experimental Covid-19 treatment. So what’s next?

2:30 p.m. ET

Sponsor Session

No Forgotten Patients: A Desired Legacy for UroGen

10 minutes

Liz Barrett, president and chief executive officer, UroGen Pharma Gideon Gil, managing editor, STAT (moderator)

2:40 p.m. ET

Lessons on health care reform

25 minutes

Deval L. Patrick, former governor of Massachusetts; founder & chairman, TogetherFUND PAC Nicholas Florko, Washington correspondent, STAT (moderator)

One of the biggest reforms in the history of U.S. health care system began in 2006 in Massachusetts. Executing the rollout fell to then-Gov. Deval Patrick. He joins STAT to discuss how lessons learned could apply to the next four years.

3:05 p.m. ET

Coffee Break

10 minutes

Sponsored by the National Pharmaceutical Council

3:15 p.m. ET

Repurposing nature’s nanotech

30 minutes

Angela M. Belcher, Ph.D., James Mason Crafts Professor of Biological Engineering and Materials Science, Massachusetts Institute of Technology

Materials scientist Angela Belcher was a finalist in our STAT Madness competition thanks to work that used carbon nanotubes to help surgeons detect ovarian tumors. She’s here to talk about how to change biology on the nanoscale.

Sponsor Introduction

Melissa Starovasnik, senior scientific advisor, research, Genentech

3:45 p.m. ET

Sponsor Session

Data vs. Disease: How Precision Medicine Is Reshaping Cancer Care

10 minutes

Stephen Gruber, M.D., M.P.H., Ph.D., director of the Center for Precision Medicine; medical oncologist, City of Hope Bina Venkataraman, editorial page editor, The Boston Globe (moderator)

Cancer is an almost unfathomably complex disease. The gap between the care patients receive and the care they should receive is widening. Find out how precision medicine helps ensure patients receive the right care at the right time — early in their disease.

3:55 p.m. ET

How much drug research will we sacrifice to save money?

30 minutes

Congresswoman Anna G. Eshoo, California’s 18th District Walid Gellad, M.D., MPH, director, Center for Pharmaceutical Policy and Prescribing, University of Pittsburgh School of Medicine Michelle McMurry-Heath, M.D., Ph.D., president & CEO, Biotechnology Innovation Organization (BIO) Ed Silverman, Pharmalot Columnist, senior writer, STAT (moderator)

For years, drug companies have argued for caution in reducing drug prices, saying there will be less research to create new medicines. But is this a real tradeoff society needs to weigh? A discussion of the real, hard truths around drug pricing.

4:25 p.m. ET

Event end and transition to breakout sessions

4:30 p.m. ET

Breakout sessions

45 minutes

Launching a drug in a pandemic — Ted W. Love, M.D., president and chief executive officer, Global Blood Therapeutics Prescription 2021 — Peter Bach, MD, MAPP, director, Center for Health Policy and Outcomes Antibody quest — George D. Yancopoulos, M.D., Ph.D., co-founder, president, and chief scientific officer, Regeneron Building a startup in a pandemic — Pearl Huang, Ph.D., president & CEO, Cygnal Therapeutics A drug hunter looks at the pandemic —George Scangos, Ph.D., chief executive officer and director, Vir Biotechnology

Limited to participants with an Attendee Pass

November 19

1 p.m. ET

Welcome from STAT

Linda Henry, CEO, Boston Globe Media Partners

1:05 p.m. ET

Bringing diversity to genetics

40 minutes

Tshaka Cunningham, Ph.D., co-founder and chief scientific officer, TruGenomix Inc. Tony Coles, M.D., executive chairman & CEO, Cerevel Therapeutics Anne Wojcicki, CEO and co-founder, 23andMe Erin Brodwin, health tech correspondent, STAT (moderator)

This year brought a reckoning to our society about racial disparities in health and medicine. These entrepreneurs are all working to solve that problem in one important arena: genetic research.

1:45 p.m. ET

Sponsor Session

Driving R&D Innovation Amid Covid-19

10 minutes

John Reed, M.D., Ph.D., executive vice president, global head of research & development, Sanofi Rick Berke, co-founder and executive editor, STAT (moderator)

John Reed, M.D., Ph.D., executive vice president, global head of research & development at Sanofi, joins us to speak about how the company’s ambitious R&D strategy, unveiled in December 2019, remains committed to driving growth and innovation amid a global pandemic while, in parallel, taking a leading role in developing a Covid-19 vaccine.

1:55 p.m. ET

Biotech’s smartest investor

25 minutes

Behzad Aghazadeh, Ph.D, managing partner & portfolio manager, Avoro Capital Advisors Adam Feuerstein, senior writer, biotech, STAT (moderator)

Behzad Aghazadeh engineered an activist takeover and turnaround of cancer drug maker Immunomedics, and then sold to Gilead Sciences for $21 billion. His $5 billion hedge fund, Avoro Capital Advisors, ranks among the top biotech stock pickers on Wall Street.

2:20 p.m. ET

Sponsor Speaker

Redefining Care: Beyond Covid-19?

5 minutes

Lynn Seely, M.D., chief executive officer, Myovant Sciences

2:25 p.m. ET

An algorithm for health

20 minutes

Regina Barzilay, Ph.D., Delta Electronics Professor, Department of Electrical Engineering and Computer Science; computer science and artificial intelligence laboratory, Massachusetts Institute of Technology Casey Ross, national technology correspondent, STAT (moderator)

After a breast cancer diagnosis, Regina Barzilay pivoted the focus of her AI research to medicine. Six years and a MacArthur grant later, she’s using algorithms to find new antibiotics and make mammograms more equitable, bridging the gap between AI research and the greater good.

2:45 p.m. ET

Coffee Break

10 minutes

Sponsored by the National Pharmaceutical Council

2:55 p.m. ET

The future of cancer detection

25 minutes

Bert Vogelstein has been one of the leading researchers in personalized medicine for more than two decades. Here, he tells the personal story of his quest for a holy grail: a blood test to detect cancer.

Bert Vogelstein, M.D., co-director of the Ludwig Center, John Hopkins Kimmel Cancer Center; investigator, Howard Hughes Medical Institute Kate Sheridan, general assignment reporter, STAT (moderator)

3:20 p.m. ET

Sponsor Session

Four lessons on changing science education

10 minutes

Scott Heimlich, vice president, Amgen Foundation; director of philanthropy, Amgen Linda Henry, CEO, Boston Globe Media Partners (moderator)

The Amgen Foundation just turned 30. Vice President Scott Heimlich will present points of wisdom from the experience.

3:30 p.m. ET

Persuading vaccine skeptics

25 minutes

Chelsea Clinton, vice chair, Clinton Foundation Helen Branswell, senior writer, infectious disease, STAT (moderator)

One of the biggest barriers to controlling Covid-19 with a vaccine will be convincing people to take it. Chelsea Clinton will discuss steps that can be taken to combat vaccine hesitancy.

4 p.m. ET

Sponsor Speaker

Closing Remarks

5 minutes

Kabir Nath, president and CEO, Otsuka North America Pharmaceutical Business

4:30 p.m. ET

Closing from STAT

5 minutes

Event concludes

Location

Online

This event was held virtually. Attendees received communications from STAT as the event approached with additional information on how to access programming and networking.